Key result
Stopping warfarin in factor V Leiden carriers shows ~11% annual recurrence, higher after idiopathic first events.
Why the study?
Does stopping warfarin treatment affect the recurrence rate in factor V Leiden carriers?
Does stopping warfarin treatment affect the recurrence rate in factor V Leiden carriers?
p-value: p=0.029
Factor V Leiden carriers with an idiopathic first event have a higher risk of recurrence when warfarin is stopped compared to those with a precipitated first event.
Factor V Leiden carriers show high recurrence after warfarin cessation, especially post-idiopathic events; leaves optimal duration open pending randomized trials.
EDITOR—Sarasin and Bounameaux's decision analysis model of treatment in factor V Leiden carriers1 is in keeping with the results of our cohort study.2 In our study the annual rate of recurrence when treatment with warfarin was stopped was 11.1 per 100 patient-years. Patients who had an idiopathic first event were more likely to have a recurrence than those whose first event was precipitated (log rank=4.76, P=0.029). The recurrence …
No takes yet. Share an insight, caveat, or question.
Baglin et al. (1998) conducted a letter in Factor V Leiden carriers. Idiopathic first event vs. Precipitated first event was evaluated on Recurrence (p=0.029). Among factor V Leiden carriers who stopped warfarin, the annual recurrence rate was 11.1 per 100 patient-years, with higher recurrence after an idiopathic versus precipitated first event (P=0.029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: